Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jing Ai

Showing results (331-340 of 409) with videos related to

Pageof 41
Sort By:
Acta Pharmacologica Sinica|September 12, 2020
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumorsZong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 13, 2025
Tailoring the Proximity of Metal-Acid in Metal/zeolite Bifunctional Catalysts for Enhanced n-Hexane HydroisomerizationJunjie Li, Yu Wang, Nan Zhang, et al.
Journal of Applied Toxicology : JAT|February 25, 2025
Exposure to Polystyrene Nanoplastics Compromise Ovarian Reserve Function and Endometrial Decidualization in Early Pregnant MiceQian-Feng Qiao, Li-Qing Wang, Qiong-Jun Xu, et al.
Journal of Natural Products|February 15, 2024
A Very Deep Graph Convolutional Network for <sup>13</sup>C NMR Chemical Shift Calculations with Density Functional Theory Level Performance for Structure AssignmentWen-Jing Ai, Jing Li, Dongsheng Cao, et al.
Heliyon|June 24, 2024
Bazi Bushen capsule attenuates cardiac systolic injury via SIRT3/SOD2 pathway in high-fat diet-fed ovariectomized miceXiaobin An, Wentao Xu, Xinyue Zhao, et al.
Molecular Cancer Therapeutics|December 15, 2017
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer ModelsJing Ai, Yi Chen, Xia Peng, et al.
Trials|December 7, 2014
Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trialJia Kou, Jie Wu, Hong-tao Yang, et al.
Acta Pharmacologica Sinica|December 8, 2020
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivoMeng-di Dai, Yue-Liang Wang, Jun Fan, et al.
Journal of Medicinal Chemistry|February 11, 2015
Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitorsYuchi Ma, Guangqiang Sun, Danqi Chen, et al.
Chinese Journal of Integrative Medicine|July 22, 2024
Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 PathwayDa-Lin Sun, Zi-Yi Guo, Wen-Yuan Liu, et al.
Pageof 41

Showing results (331-340 of 409) with videos related to

Sort By:
Pageof 41
Acta Pharmacologica Sinica|September 12, 2020
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumorsZong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, et al.
Small (Weinheim an Der Bergstrasse, Germany)|December 13, 2025
Tailoring the Proximity of Metal-Acid in Metal/zeolite Bifunctional Catalysts for Enhanced n-Hexane HydroisomerizationJunjie Li, Yu Wang, Nan Zhang, et al.
Journal of Applied Toxicology : JAT|February 25, 2025
Exposure to Polystyrene Nanoplastics Compromise Ovarian Reserve Function and Endometrial Decidualization in Early Pregnant MiceQian-Feng Qiao, Li-Qing Wang, Qiong-Jun Xu, et al.
Journal of Natural Products|February 15, 2024
A Very Deep Graph Convolutional Network for <sup>13</sup>C NMR Chemical Shift Calculations with Density Functional Theory Level Performance for Structure AssignmentWen-Jing Ai, Jing Li, Dongsheng Cao, et al.
Heliyon|June 24, 2024
Bazi Bushen capsule attenuates cardiac systolic injury via SIRT3/SOD2 pathway in high-fat diet-fed ovariectomized miceXiaobin An, Wentao Xu, Xinyue Zhao, et al.
Molecular Cancer Therapeutics|December 15, 2017
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer ModelsJing Ai, Yi Chen, Xia Peng, et al.
Trials|December 7, 2014
Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trialJia Kou, Jie Wu, Hong-tao Yang, et al.
Acta Pharmacologica Sinica|December 8, 2020
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivoMeng-di Dai, Yue-Liang Wang, Jun Fan, et al.
Journal of Medicinal Chemistry|February 11, 2015
Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitorsYuchi Ma, Guangqiang Sun, Danqi Chen, et al.
Chinese Journal of Integrative Medicine|July 22, 2024
Astragaloside IV Alleviates Podocyte Injury in Diabetic Nephropathy through Regulating IRE-1α/NF-κ B/NLRP3 PathwayDa-Lin Sun, Zi-Yi Guo, Wen-Yuan Liu, et al.
Pageof 41